Zhang Liping, Wang Fen, He Hualiang, Jiao Tingting, Wu Lili
Endocrinology Department, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China.
Emergency Department, Armed Police Force Beijing General Hospital, Beijing, China.
Evid Based Complement Alternat Med. 2021 Nov 25;2021:1089176. doi: 10.1155/2021/1089176. eCollection 2021.
Dysregulation of gut microbiota contributes to the development of type 2 diabetes. To investigate the antidiabetic effect of Tangnaikang and its regulation of gut microbiota in diabetic KKAy mice, a type 2 diabetes mouse model was established by feeding KKAy mice with a high-fat diet (HFD) for 2 weeks. The diabetic KKAy mice were treated with vehicle, Acarbose, or different doses of Tangnaikang once a day for 8 weeks. The fasting plasma glucose (FPG) levels and bodyweights were measured weekly. The fecal and blood samples were collected 8 weeks after treatment. The 16s rRNA sequencing and bioinformatics analysis were conducted to explore the effects of Tangnaikang treatment on the richness, diversity, and relative abundance of gut microbiota. Compared with other treatments, high-dose Tangnaikang (4.68 g/kg) significantly reduced FPG levels while elevating bodyweights in model mice. Compared with saline treatment, different doses of Tangnaikang significantly increased gut microbial species richness and diversity. Linear discriminant analysis effect size identified potential bacterial biomarkers associated with Tangnaikang treatment. Relative abundance analysis revealed that Tangnaikang treatment modulated the abundance of gut bacteria at the class and genus levels, such as , and . The principal component analysis demonstrated that, compared with the samples of the high-dose group, the samples of medium-dose and low-dose groups were closer to those of the model group. Tangnaikang alleviated hyperglycemia and improved the composition and abundance of gut microbiota in diabetic KKAy mice.
肠道微生物群失调会导致2型糖尿病的发生。为了研究糖奈康对糖尿病KKAy小鼠的抗糖尿病作用及其对肠道微生物群的调节作用，通过给KKAy小鼠喂食高脂饮食（HFD）2周建立了2型糖尿病小鼠模型。糖尿病KKAy小鼠每天接受一次赋形剂、阿卡波糖或不同剂量的糖奈康治疗，持续8周。每周测量空腹血糖（FPG）水平和体重。治疗8周后收集粪便和血液样本。进行16s rRNA测序和生物信息学分析，以探讨糖奈康治疗对肠道微生物群丰富度、多样性和相对丰度的影响。与其他治疗相比，高剂量糖奈康（4.68 g/kg）显著降低了模型小鼠FPG水平，同时增加了体重。与生理盐水治疗相比，不同剂量的糖奈康显著增加了肠道微生物物种的丰富度和多样性。线性判别分析效应大小确定了与糖奈康治疗相关的潜在细菌生物标志物。相对丰度分析显示，糖奈康治疗在纲和属水平上调节了肠道细菌的丰度，如、和。主成分分析表明，与高剂量组样本相比，中剂量和低剂量组样本更接近模型组样本。糖奈康减轻了糖尿病KKAy小鼠的高血糖，并改善了肠道微生物群的组成和丰度。
